Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

BioCardia

Cardiovascular

Cardiovascular Today—March 5, 2026

This week’s Cardiovascular update highlights regulatory clearances, late-stage…

Cardiovascular

Cardiovascular Weekly News - October 2nd 2025

Cardiovascular Update: CardiAMP cell therapy, GBD special report, EU steps up…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Obesity Today—March 24, 2026
Endocrinology Today—March 24, 2026
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines
Oncology Today—March 23, 2026

Tags

AAV-based gene therapies ACIP adaptive design American Academy of Pediatrics American Society of Clinical Oncology AngioVac Atherosclerosis treatments Ayrmid brain aging cancer care cancer vaccines Cell and gene therapy pipeline CKD anemia clinicaltrials competitive advantage continuous bioprocessing CVC datasecurity digital health innovation Digital health transformation digital pill drug development fair pricing FDA Orphan Drug Designation Fertility Formation Bio google ventures HeartFlow HER2 antibody-drug conjugate Kymera Therapeutics Lexicon Pharmaceuticals mental health Mismatch repair deficiency Neuroscience drug pipeline Oncology market trends OSE Immunotherapeutics Ovarian Function Suppression Pain Paroxysmal supraventricular tachycardia patient centricity PrecisionMedicine Series B Tecvayli US health crisis VOICE ASSISTANT

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Obesity Today—March 24, 2026
Endocrinology Today—March 24, 2026
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines
Oncology Today—March 23, 2026

TAGS

AAV-based gene therapies ACIP adaptive design American Academy of Pediatrics American Society of Clinical Oncology AngioVac Atherosclerosis treatments Ayrmid brain aging cancer care cancer vaccines Cell and gene therapy pipeline CKD anemia clinicaltrials competitive advantage continuous bioprocessing CVC datasecurity digital health innovation Digital health transformation digital pill drug development fair pricing FDA Orphan Drug Designation Fertility Formation Bio google ventures HeartFlow HER2 antibody-drug conjugate Kymera Therapeutics Lexicon Pharmaceuticals mental health Mismatch repair deficiency Neuroscience drug pipeline Oncology market trends OSE Immunotherapeutics Ovarian Function Suppression Pain Paroxysmal supraventricular tachycardia patient centricity PrecisionMedicine Series B Tecvayli US health crisis VOICE ASSISTANT

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy